Prognostic significance of hyperfibrinogenemia in patients with lower-risk myelodysplastic syndromes
Ann Hematol
.
2020 Jan;99(1):189-191.
doi: 10.1007/s00277-019-03863-z.
Epub 2019 Nov 26.
Authors
Shinji Ogura
1
,
Shoichiro Yonei
1
,
Tomohiko Tanigawa
1
,
Masahiro Akimoto
1
,
Aki Sakurai
1
,
Yuriko Fujita
1
,
Chisako Ito
1
,
Yoshinobu Aisa
1
,
Tomonori Nakazato
2
Affiliations
1
Department of Hematology, Yokohama Municipal Citizen's Hospital, 56 Okazawa-cho, Hodogaya-ku, Yokohama, 240-8555, Japan.
2
Department of Hematology, Yokohama Municipal Citizen's Hospital, 56 Okazawa-cho, Hodogaya-ku, Yokohama, 240-8555, Japan. n-tomo@eurus.dti.ne.jp.
PMID:
31773214
DOI:
10.1007/s00277-019-03863-z
No abstract available
Publication types
Letter
MeSH terms
Adult
Aged
Aged, 80 and over
Disease-Free Survival
Female
Fibrinogen / metabolism*
Humans
Male
Middle Aged
Myelodysplastic Syndromes / blood*
Myelodysplastic Syndromes / mortality*
Retrospective Studies
Survival Rate
Substances
Fibrinogen